無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

インスリングラルギンの中国市場の分析

Investigation Report on Chinese Insulin Glargine Market, 2018-2022

発行 China Research and Intelligence 商品コード 674762
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
インスリングラルギンの中国市場の分析 Investigation Report on Chinese Insulin Glargine Market, 2018-2022
出版日: 2018年08月06日 ページ情報: 英文 30 Pages
概要

インスリングラルギンは、組換えDNA技術を応用した持続型インスリン製剤で、2000年にアメリカ食品医薬品局(FDA)および欧州医薬品庁(EMA)に承認されました。中国におけるインスリングラルギンの売上額は2017年に8億中国元に達しました。

当レポートでは、世界のインスリングラルギン市場を調査し、製品の概要、中国全体および地域別の売上の推移、製品価格、主要企業の動向分析、市場の見通しなどについて包括的にまとめています。

第1章 インスリングラルギンの概要

  • インスリングラルギンの適応症
  • 中国におけるインスリングラルギンの開発の沿革
  • 中国におけるインスリングラルギンの特許および政府承認

第2章 中国におけるインスリングラルギンの売上の推移(実績値)

  • インスリングラルギンの売上額
    • 売上額:全体
    • 売上額:地域別
  • インスリングラルギンの売上量
    • 売上量:全体
    • 売上量:地域別
  • インスリングラルギンの剤型

第3章 インスリングラルギンの主要メーカー

  • 主要メーカーの市場シェア
    • 市場シェア:金額ベース
    • 市場シェア:重量ベース
  • Aventis Behring
  • Gan & Lee Pharmaceuticals
  • Heilongjiang Jiangshi Pharmaceutical Co., Ltd.
  • Nanjing Xinbai Pharmaceutical Co., Ltd.
  • Zhuhai United Laboratories Co., Ltd.

第4章 インスリングラルギンの価格

  • Aventis Behring (Lantus)
  • Gan & Lee Pharmaceuticals (Changxiulin)
  • Zhuhai United Laboratories Co., Ltd. (USLEN)

第5章 中国のインスリングラルギン市場の見通し

  • インスリングラルギン開発への影響要因
  • 市場規模の予測
  • 市場動向の予測

表リスト

目次
Product Code: 1808325

Description

With the development of China's economy, the improvement of residents' living standard, the change of lifestyle and the aging of population, diabetes is seeing a rising prevalence and has become the third most serious chronic disease that threatens human health next to tumors and cardiovascular diseases.

According to WHO's data, there are about 110 million diabetics in China, about 1/10 of China's adults. And the number will increase to 150 million in 2040 if no swift actions are taken to reduce the risk factors such as unhealthy diet and lack of exercises. The rapid growth of diabetes has placed a heavy burden on China's social and economic development.

Insulin Glargine is the first long-acting insulin produced by simulating recombinant DNA technology. It was approved to be put into use by FDA in Apr. 2000 and then by the European Agency for the Evaluation of Medicinal Products (EMEA) in Jun. 2000. The sales value has been growing since Insulin Glargine entered China and exceeded CNY 800 million in 2017.

In China, the third generation of insulin is still under promotion. Due to the relatively high price, it has not yet dominated the market. The second and third generations of insulin will form a market pattern of dislocation competition.

Because Insulin Glargine is mainly produced by genetic engineering methods, the threshold of production technology is relatively high. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap. Hence manufacturers must attain an industrial production of large scale, low cost and mature technology to gain profits. At present, the Chinese market is dominated by Aventis Behring's brand-name drug and the generic drugs of Gan & Lee Pharmaceuticals and Zhuhai United Laboratories Co., Ltd. However, it is expected that the market pattern in China will change in the next few years as some domestic enterprises are speeding up the development of generic Lantus.

According to CRI, the incidence of diabetes keeps increasing in China with the improvement of people's living standard and the change of lifestyle, which expands the diabetes drug market year by year. The market size of diabetes drugs in China exceeded CNY 30 billion in 2017. The third-generation insulin products have been technically improved, reduced some shortcomings of the second-generation products, and effectively shortened the treatment time. They are expected to completely replace the second-generation insulin in the future. It is foreseeable that Insulin Glargine is the product with most growth potential among the three generations of insulin products in China, and its market size will continue to grow from 2018 to 2022.

Topics Covered:

  • Development environment of Insulin Glargine
  • Supply of and demand for Insulin Glargine in China
  • Major Insulin Glargine manufacturers in China
  • Prices of Insulin Glargine in China
  • Factors influencing the development of the Chinese Insulin Glargine market from 2018 to 2022
  • Prospect of the Chinese Insulin Glargine market from 2018 to 2022

Table of Contents

1 Relevant Concepts of Insulin Glargine

  • 1.1 Indications for Insulin Glargine
  • 1.2 Development History of Insulin Glargine in China
  • 1.3 Patents and Government Approval on Insulin Glargine in China

2 Sales of Insulin Glargine in China, 2013-2017

  • 2.1 Sales Value of Insulin Glargine
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Insulin Glargine
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Insulin Glargine by Dosage Form in China, 2013-2017

3 Analysis on Major Insulin Glargine Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Insulin Glargine Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Aventis Behring
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Aventis Behring's Insulin Glargine in China
  • 3.3 Gan & Lee Pharmaceuticals
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Gan & Lee Pharmaceuticals' Insulin Glargine in China
  • 3.4 Zhuhai United Laboratories Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine in China

4 Prices of Different Manufacturers' Insulin Glargine in China, 2017-2018

  • 4.1 Overview
  • 4.2 Aventis Behring (Lantus)
  • 4.3 Gan & Lee Pharmaceuticals (Changxiulin)
  • 4.4 Zhuhai United Laboratories Co., Ltd. (USLEN)

5 Prospect of Chinese Insulin Glargine Market, 2018-2022

  • 5.1 Analysis on Factors Influencing Development
  • 5.2 Forecast on Market Trend
  • 5.3 Analysis on Generic Drugs in Development

Selected Charts

  • Chart Governmental Approval of Insulin Glargine in China
  • Chart Sales Value of Insulin Glargine in China, 2013-2017
  • Chart Sales Value of Insulin Glargine in Parts of China, 2013-2017
  • Chart Sales Volume of Insulin Glargine in China, 2013-2017
  • Chart Sales Value and Market Share of Aventis Behring's Insulin Glargine in China, 2013-2017
  • Chart Sales Value and Market Share of Gan & Lee Pharmaceuticals' Insulin Glargine in China, 2013-2017
  • Chart Sales Value and Market Share of Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine in China, 2013-2017
  • Chart Sales Value and Market Share of Insulin Glargine Injections in China, 2013-2017
  • Chart Prices of Aventis Behring's Insulin Glargine in Parts of China, 2017-2018
  • Chart Prices of Gan & Lee Pharmaceuticals' Insulin Glargine in Parts of China, 2017-2018
  • Chart Prices of Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Insulin Glargine in China, 2018-2012
Back to Top